






AZBT12128(TRK A Inhibitor NTRK Fusion Cancer)





❖ MOA: Selectively inhibiting TRK to treat NTRK fusion cancer



Growth Point 1 Overcoming Tolerance of type1

Growth Point 2 Precision diagnosis for anticancer treatment



- Tolerance to Type 1 treatment
Solvent front mutation
- Adverse effects from off-target inhibition.
- Type 2 TRK inhibition to overcome the tolerance of type 1.
- Selective inhibition on TRK A, less adverse effects from off target inhibition.

- Precision diagnosis for anticancer treatment through collaborative R&D with genetic testing company (NGS test)
- Optimizing leads with

